#United States #Salt Lake City #Sera Prognostics #Health Care #PreTRM Test

Sera Prognostics to Present at TD Cowen Health Care Conference

Sera Prognostics Inc., recognized as The Pregnancy Company®, has made headlines by announcing its presentation at the highly anticipated TD Cowen 45th Annual Health Care Conference scheduled for March 5, 2025. The event will provide a platform for discussions around pivotal advancements in maternal and neonatal health, which is Sera’s primary focus.

Overview of the Presentation

The presentation will be led by Zhenya Lindgardt, the company’s President and CEO. Scheduled for a time slot between 9:50 a.m. and 10:20 a.m. ET, Lindgardt is set to engage in a fireside chat, where he will discuss the latest achievements and strategic directives of Sera Prognostics. This presentation aims to showcase the company's commitment to enhancing health outcomes for mothers and their newborns through innovative approaches in pregnancy care.

A live webcast of the presentation will be available, allowing stakeholders, healthcare professionals, and interested parties to tune in. The recorded version will also be accessible on Sera Prognostics’ investor relations page for those unable to attend the live session.

Sera Prognostics: A Leader in Maternal Health

Sera Prognostics operates at the forefront of health diagnostics, particularly focusing on the health implications during pregnancy. The company strives to equip healthcare professionals with vital information that can guide the timely intervention of potential pregnancy-related complications. One of its standout offerings is the PreTRM® Test, which predicts the risk of spontaneous premature birth.

Understanding Preterm Birth

Preterm birth, classified as delivery occurring before 37 weeks of gestation, remains a pressing global health concern. It is a significant contributor to neonatal morbidity and mortality. According to the March of Dimes Report, over 10% of infants in the United States are born prematurely, highlighting the urgency for effective monitoring and intervention strategies. Consequently, Sera Prognostics is dedicated to tackling this challenge head-on through its innovative testing processes, aiming to reduce the incidence and impact of preterm births.

The Innovative PreTRM® Test

At the heart of Sera Prognostics' offerings lies the PreTRM® Test, hailed as a breakthrough in prenatal care. It is the only commercially available blood biomarker test offering an accurate prediction of preterm birth risk for asymptomatic singleton pregnancies. By analyzing specific proteins in the blood, the PreTRM® Test provides healthcare providers with critical insights into which patients require focused care and monitoring. This empowers clinicians to make informed decisions and administer proactive treatments tailored to the individual risk profile of expectant mothers.

The test is generally performed during pregnancy weeks 18 to 20, assuring early detection of risk that can lead to timely interventions. Through this, Sera Prognostics endeavors to improve overall pregnancy outcomes while simultaneously mitigating the healthcare costs associated with complications arising from prematurity.

Conclusion

Sera Prognostics continues to lead the charge in improving maternal and neonatal health through technological advancement and innovative testing solutions. By participating in key conferences like that of TD Cowen, the company not only disseminates pivotal information regarding its groundbreaking initiatives but also aligns itself with the critical conversations shaping the future of health diagnostics in pregnancy care. As the health community eagerly anticipates the upcoming presentation, Sera’s contributions and the substantial data it shares will undoubtedly provoke discussion and possibly pave the way for future innovative health solutions.